---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-24-012263"
form_type: "8-K"
ticker: "HIND"
cik: "0001427570"
company_name: "Vyome Holdings, Inc"
filed_at: "2024-08-14T23:59:59+00:00"
generated_at: "2026-05-31T09:17:28.322411+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# ReShape Lifesciences enters merger with Vyome Therapeutics, sells assets to Biorad for $5.16M

## Summary
- Q2 revenue $2.0M (-12.8% YoY); six-month revenue $3.9M (-13.9% YoY); gross margin improved to 57.7%.
- Operating expenses down 45.4% in first half; sales & marketing fell 69.2% in Q2 to $0.7M.
- Cash and restricted cash $1.2M as of June 30, with net working capital $2.9M.
- Merger with Vyome: all-stock deal; ReShape stockholders to own ~11.1% of combined company.
- Asset sale to Biorad Medisys for $5.16M cash; assets include Lap-Band and Obalon systems.

## SEC filing metadata
- accession: 0001558370-24-012263
- form_type: 8-K
- ticker: HIND
- cik: 0001427570
- company_name: Vyome Holdings, Inc
- filed_at: 2024-08-14T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1427570/000155837024012263/0001558370-24-012263-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1427570/000155837024012263/rsls-20240814x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-24-012263
- JSON: https://secwatch.observer/filing/0001558370-24-012263.json
- Plain text: https://secwatch.observer/filing/0001558370-24-012263.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.